Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. | Monte Rosa ...

Monte Rosa Therapeutics' stock falls as MRT-2359 faces challenges in targeting CRPC. Click here to read an analysis of GLUE ...

Monte Rosa Therapeutics, Inc.’s GLUE share price has dipped by 17.85%, which has investors questioning if this is right time ...

Monte Rosa reported that one of its molecular glue degraders had seen a strong response in immune disorders, but another fell ...

Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Monte Rosa Therapeutics (NASDAQ:GLUE – Free Report) had its target price trimmed by Wells Fargo & Company from $11.00 to $10.00 in a research note released on Friday morning,Benzinga reports.

Reports Q4 revenue $60.6M, consensus $51.9M. “We continue to make excellent progress with our clinical and preclinical molecular glue degrader ...

Monte Rosa Therapeutics, a US biotech developing novel molecular glue degrader (MGD)-based medicines, closed Thursday’s ...

Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...

BOSTON - Monte Rosa Therapeutics , Inc. (NASDAQ: GLUE) reported fourth quarter revenue that significantly exceeded analyst expectations, sending shares up 6.9% in early trading.